Since we applied the intron- and exon-based strategies for genetic correction of SCA3 disease, our genetically corrected cells expressed full-length ataxin-3 protein to ensure the normal function of ataxin-3 protein. The gene discussed is ATXN3; the disease is Machado-Joseph disease.